# A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer

> **NCT02874664** · PHASE1 · COMPLETED · sponsor: **Stemcentrx** · enrollment: 46 (actual)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Rovalpituzumab Tesirine

## Key facts

- **NCT ID:** NCT02874664
- **Lead sponsor:** Stemcentrx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2018-09-12
- **Final completion:** 2018-09-12
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2018-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02874664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02874664, "A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02874664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*